China’s KRAS Race: Homegrown Contenders Play Catch-Up

Gaining On In-Licensed Assets

 
• By Dexter Jie Yan
  
balance
balance seems to have been tipped towards home-grown KRAS G12C inhibitors in China • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia